


Supporting the Development of **Infectious Diseases** **molecule treatments** coming off patent in the next few years

We are now supporting you through all the stages in a drug development continuum



Infectious Disease Drugs Coming Off Patent in the next few years



Major Drugs for Infectious Disease Going off Patent between 2023-2030

Are you eyeing them?

Molecule Name	Therapeutic Indication	Year of Patent Expiry
Raltegravir	Used along with other medications to treat HIV-1 infection in adults & paediatric patients who weigh at least 2kg.	2023
Emtricitabine Tenofovir Disoproxil	NRTI is indicated for treating HIV infection in adults	2024
Efavirenz Emtricitabine Tenofovir Disoproxil	This combination treats HIV infection in adults and children weighing more than 40 kg.	2024
Abacavir Dolutegravir Lamivudine	Indicated to treat infection caused by HIV	2027
Dolutegravir	Indicated to treat HIV infection in combination with other medications	2027
Ledipasvir Sofosbuvir	Indicated to treat Chronic Hepatitis C	2028
Cobicistat Elvitegravir Emtricitabine Tenofovir Alafenamide	Increases systemic exposure to other antiretroviral drugs.	2030
Sofosbuvir Velpatasvir	Indicated to treat Chronic Hepatitis C	2029
Cobicistat Elvitegravir Emtricitabine	Indicated to treat infection caused by HIV	2029
Darunavir Cobicistat	Indicated to treat infection caused by HIV	2029

Accelerate the Development of your Infectious Disease Drug or Vaccine from concept through commercialization with Veeda Group

Study Design and Execution

Site Monitoring and Safety Monitoring

Project Management

Clinical Pharmacology Services

Volunteer Recruitment

Pharmacy & Bioanalytical services

Conducting Feasibility & Site Set up activity

Regulatory Guidance

Our Experience in Vaccine Studies

Vaccine Studies	Short Description	Study Status
IgG Titer Studies	<ul style="list-style-type: none"> IgG Titre Clinical studies involve the measurement of human anti-SP/RBD IgG titers in human serum samples RBD Specific target Method optimization and Validation, followed by clinical studies 	Ongoing
ELISPOT Studies	<ul style="list-style-type: none"> The enzyme-linked immunospot ELISPOT assay is a highly sensitive immunoassay that measures the frequency of cytokine-secreting cells at the single-cell with PBMC isolation & culturing 	Ongoing
COVID-19 Study	<ul style="list-style-type: none"> Open-label bridging study followed by a double-blind Phase II/III study of AKS-452 (a second-generation protein sub-unit vaccine against COVID-19) No of Subjects: 100 (Bridging) 1500 (Phase II/III study) 	Ongoing
Polio Vaccine Study	<ul style="list-style-type: none"> Open Label Phase 1 Clinical Study for Evaluation of Safety and Immunogenicity of Sabin-based Inactivated Polio Vaccine in Healthy Adult Human Male Subjects No. of subjects- 24 	Completed

Our Ongoing Study on Antiretroviral Drugs

Study Name	Study Status
A Phase 1, Open-label, Multiple-dose, Two-treatment, Three-period, Non-randomized Single Sequence, Steady State, two-way Interaction Study Under Fasting Conditions to Evaluate the Pharmacokinetic Interactions Between HRF-10071 and Tenofovir alafenamide/ Emtricitabine.	Ongoing

[Check our latest PK/ADA list](#)

Our Team has Cumulative Experience in the Design and Execution of Clinical Trials on drugs indicated for Bacterial, Skin, and Hepatitis B infections

Validated Method Library on Drugs for Infectious Diseases

Drug Name		
Azithromycin	Levofloxacin	Clindamycin
Cefaclor	Moxifloxacin	Dicloxacillin
Cefadroxil	Norfloxacin	Doxycycline
Cefditoren	Ofloxacin	Emtricitabine + Tenofovir Alafenamide
Cefixime	Sulfadiazine	Entecavir
Cefpodoxime Acid	Sulphamethoxazole + Trimethoprim	Etravirine
Cefuroxime Acid	Sulfadoxine	Lamivudine
Cephalexin	Favipiravir	Nevirapine
Linezolid	Abacavir	Lamivudine + Tenofovir
Minocycline	Abacavir + Lamivudine	Lamivudine + Zidovudine
Nafithromycin	Acyclovir	Lamivudine + Abacavir
Nitrofurantoin	Amantadine	Lamivudine + Nevirapine + Zidovudine
Rifaximin	Atazanavir	Ledipasvir + Sofosbuvir
Tetracycline	Dolutegravir	Maraviroc
Erythromycin	Dolutegravir + Emtricitabine + Tenofovir Alafenamide	Oseltamivir + Oseltamivir Carboxylate
Amoxicillin	Efavirenz	Raltegravir
Ciprofloxacin	Emtricitabine	Sofosbuvir
Clarithromycin	Emtricitabine + Tenofovir	Tenofovir
Tenofovir+ Emtricitabine	Tenofovir + Emtricitabine + Rilpivirine	Tenofovir + Emtricitabine + Lamivudine
Tenofovir + Emtricitabine + Nevirapine	Terbinafine	Tenofovir Alafenamide + Lamivudine
Valacyclovir + Acyclovir	Valganciclovir + Ganciclovir	Voriconazole (Sensitive)
Amphotericin B (Free)	Amphotericin B (Liposomal)	Total Amphotericin
Fluconazole	Flucytosine	Griseofulvin
Itraconazole	Itraconazole + Hydroxy Itraconazole	Posaconazole

We deliver a holistic suite of services essential to Infectious Disease Drug candidates & Vaccine Development

- **Experienced and Qualified Safety Team**

79 MD physicians especially for Infectious Diseases are associated across 25 sites

- **Well-equipped and maintained special care area to handle medical emergencies**

Veeda Group Advantage

Extensive Scientific Competence to service a Diverse client base

One of the largest Independent Full Service CRO's in India

High Customer Centricity and Satisfaction

Robust Quality & Regulatory Compliance

Skilled personnel with focus on Continuous Professional Development

One stop solution for complex studies

To know more about our expertise in infectious disease drugs or vaccine trials, mail us at

info@veedacr.com

Partners in creating a healthier tomorrow

 +91 7967773000

 www.veedacr.com